Extended indication Glioblastoma multiforme, 1L adjuvant.
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Brain cancer vaccine
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication Brain cancer
Extended indication Glioblastoma multiforme, 1L adjuvant.
Proprietary name DCVax-L
Manufacturer Northwest
Mechanism of action Cancer vaccine
Route of administration Intrader meal
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug Yes
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
References NCT00045968

Expected patient volume per year

Patient volume

200

Market share is generally not included unless otherwise stated.

References Expertopinie; IKNL
Additional remarks In Nederland zijn er jaarlijks ongeveer 1.100 patiënten met de diagnose glioma waarbij er ongeveer 750 een pathologisch bevestigde diagnose glioblastoma krijgen. Voor een dergelijk vaccin zal er sprake moeten zijn van meer dan enkel een biopsie als diagnostische resectie. Over de jaren 2014-2017 is de verhouding biopt versus resectie 28,7% versus 71,3%. (215 versus 535 patiënten).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Lung Cancer Brain Metastases & Brain Metastases From Breast Cancer
References clinicaltrials.gov

Other information

There is currently no futher information available.